VIA
ESPR

Virtus Investment Advisers’s Esperion Therapeutics ESPR Stock Holding History

Virtus Investment Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-219,293
Closed -$601K – 479
2026
Q1 		$601K Buy
219,293
+41,785
+24% +$132K 0.17% 198
2025
Q4 		$657K Buy
+177,508
New +$574K 0.18% 200
2025
Q2 		– Sell
-140,800
Closed -$203K – 458
2025
Q1 		$203K Buy
+140,800
New +$259K 0.06% 263

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Virtus Investment Advisers's ESPR Position: Q2 2026 in Review

Virtus Investment Advisers sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 219,293 shares — an estimated $601K sold.

Virtus Investment Advisers first reported a position in ESPR in Q1 2025 and held it in 3 quarters. The position peaked at $657K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Virtus Investment Advisers reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtus Investment Advisers sold 219,293 Esperion Therapeutics shares in Q2 2026, an estimated $601K.
  • Virtus Investment Advisers first reported a position in Esperion Therapeutics in Q1 2025 and held it in 3 quarters.
  • Virtus Investment Advisers's Esperion Therapeutics position peaked at $657K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.